Previous Close | 9.00 |
Open | 9.14 |
Bid | 8.87 x 1000 |
Ask | 9.01 x 800 |
Day's Range | 8.75 - 9.14 |
52 Week Range | 2.56 - 11.67 |
Volume | |
Avg. Volume | 161,103 |
Market Cap | 402.567M |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.59 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for EPIX
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting").
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan, the global outlook for securities markets in 2024 suggests a more positive scenario compared to the previous year, with […]
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Majority of Patients in Phase 1/2 Clinical Trial of Masofaniten at High Risk for Early Enzalutamide Failure In January 2024, ESSA Pharma Inc. (NASDAQ:EPIX) announced that updated Phase 1/2 clinical trial data for masofaniten (formerly EPI-7386) in combination with enzalutamide (Enz) was presented at the 2024 ASCO